S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$14.82
-0.05 (-0.34%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.61
▼
$14.82
50-Day Range
$12.42
▼
$14.87
52-Week Range
$12.28
▼
$15.36
Volume
1.64 million shs
Average Volume
2.23 million shs
Market Capitalization
$45.95 billion
P/E Ratio
27.44
Dividend Yield
1.86%
Price Target
$24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
61.9% Upside
$24.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.02mentions of Takeda Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

128th out of 1,034 stocks

Pharmaceutical Preparations Industry

46th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

December 2, 2022 | finance.yahoo.com
Global Blood Plasma Derivatives Market Report 2022: Featuring Bayer, Takeda Pharmaceutical, Grifols, Biotest & More
November 30, 2022 | finance.yahoo.com
Japan’s Government Stayed Out of Currency Markets in November
November 27, 2022 | marketwatch.com
Actovegin Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028
November 26, 2022 | marketwatch.com
Insomnia Medication Market 2022 : Projected to Deliver Greater Revenues during the Forecast Period 2028
November 25, 2022 | marketwatch.com
Ewing Sarcoma Drugs Market : Analysis by Size, Share Trends, Future Growth, Emerging Trends, Qualitative Outlook and Global Forecast to 2028
November 22, 2022 | finance.yahoo.com
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
November 18, 2022 | uk.finance.yahoo.com
Lyophilization in pharmaceuticals market is projected to grow at a CAGR of 13.0% by 2033: Visiongain Reports Ltd
November 17, 2022 | finance.yahoo.com
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 11, 2022 | marketwatch.com
What's Driving the Amyotrophic Lateral Sclerosis Treatment Market Growth 2022-2026?
November 11, 2022 | finance.yahoo.com
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 9, 2022 | marketwatch.com
Eptifibatide Injection Market Trends 2023 Growth Factor, Industry Challenge, Share, Business Overview, Size and Forecast to 2028
November 8, 2022 | finance.yahoo.com
THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA
November 4, 2022 | benzinga.com
Next Generation Antibody Therapeutics Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence
October 27, 2022 | marketwatch.com
Takeda Pharmaceutical 2Q Net Profit Y61.74B, Given Y105.01B Net Profit in 1Q, WSJ Calculation Shows
October 27, 2022 | markets.businessinsider.com
Takeda H1 Profit Down, Revenues Rise; Lifts FY22 Outlook - Quick Facts
October 27, 2022 | marketwatch.com
Takeda Pharmaceutical Second-Quarter Net Profit Missed Analysts' Expectations -- Earnings Review
October 26, 2022 | benzinga.com
Global Diabetes Therapeutics Market Report to 2030 - Featuring Novartis, Novo Nordisk, Sanofi and Takeda Pharmaceutical Among Others
October 20, 2022 | finance.yahoo.com
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 16, 2022 | markets.businessinsider.com
Takeda: CHMP Recommends Approval Of Dengue Vaccine Candidate, TAK-003
October 15, 2022 | msn.com
EU regulator recommends clearing Takeda’s dengue vaccine
October 14, 2022 | reuters.com
EU regulator backs Takeda's dengue vaccine
October 14, 2022 | washingtonpost.com
EU regulator recommends clearing Takeda's dengue vaccine
October 14, 2022 | finance.yahoo.com
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 12, 2022 | finance.yahoo.com
Global Insomnia Market Report to 2030 - Featuring Currax Pharmaceuticals, Eisai, Minerva Neurosciences and Pfizer Among Others
October 12, 2022 | nz.finance.yahoo.com
Pharmaceutical Drugs Industry: Global Competitive Landscape 2021
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
10/27/2022
Today
12/04/2022
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+61.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.54
Trailing P/E Ratio
27.44
Forward P/E Ratio
7.06
P/E Growth
0.65
Net Income
$2.05 billion
Net Margins
5.60%
Pretax Margin
5.86%
Return on Equity
12.76%
Return on Assets
5.61%

Debt

Debt-to-Equity Ratio
0.62
Current Ratio
1.15
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$31.79 billion
Price / Sales
1.45
Cash Flow
$3.58 per share
Price / Cash Flow
4.14
Book Value
$15.59 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
3,100,720,000
Free Float
3,099,482,000
Market Cap
$45.95 billion
Optionable
Optionable
Beta
0.71

Social Links


Key Executives

  • Mr. Christophe Weber (Age 56)
    Pres, CEO & Representative Director
    Comp: $4.02M
  • Mr. Constantine Saroukos (Age 51)
    CFO & Representative Director
    Comp: $2.4M
  • Dr. Andrew S. Plump (Age 57)
    Pres of R&D and Representative Director
    Comp: $2.28M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 65)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 44)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

4 brokers have issued 1-year price targets for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $24.00 to $24.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 61.9% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2022?

Takeda Pharmaceutical's stock was trading at $13.63 at the beginning of the year. Since then, TAK stock has increased by 8.7% and is now trading at $14.82.
View the best growth stocks for 2022 here.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest in November. As of November 15th, there was short interest totaling 5,550,000 shares, an increase of 39.1% from the October 31st total of 3,990,000 shares. Based on an average trading volume of 3,020,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.2% of the shares of the stock are short sold.
View Takeda Pharmaceutical's Short Interest.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our TAK earnings forecast.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted its earnings results on Thursday, October, 27th. The company reported $0.52 earnings per share for the quarter. The company earned $7.26 billion during the quarter. Takeda Pharmaceutical had a net margin of 5.60% and a trailing twelve-month return on equity of 12.76%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.28 per share and currently has a dividend yield of 1.86%. The dividend payout ratio is 51.85%. This payout ratio is at a healthy, sustainable level, below 75%.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of $3.80-$3.80 for the period. The company issued revenue guidance of $28.46 billion-$28.46 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (0.13%), Renaissance Technologies LLC (0.09%), BlackRock Inc. (0.07%), Brandes Investment Partners LP (0.06%), Van ECK Associates Corp (0.06%) and Barclays PLC (0.05%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $14.82.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $45.95 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.54 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 12/4/2022 by MarketBeat.com Staff